Patent · US Active

Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis

US7728115B2 · kind B2 · utility

2Cited by
5References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 2, 2005
Grant dateJun 1, 2010
Priority date
Expiry dateJun 10, 2027

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S530/866
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.